Amphastar Pharmaceuticals
AMPH
205 hedge funds and large institutions have $839M invested in Amphastar Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 80 increasing their positions, 80 reducing their positions, and 37 closing their positions.
196% more call options, than puts
Call options by funds: $2.77M | Put options by funds: $935K
0% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 80
1.69% less ownership
Funds ownership: 62.58% → 60.89% (-1.7%)
8% less funds holding
Funds holding: 223 → 205 (-18)
21% less capital invested
Capital invested by funds: $1.06B → $839M (-$224M)
46% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 37
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.1M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$5.47M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.37M |
| 4 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
+$2.73M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
-$11.9M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.94M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
-$6.7M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$5.69M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$5.22M |
AMPH Hedge Fund Activity: Q3 2022 in Review
205 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2022, worth a combined $839M — down 21% from $1.06B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of AMPH and 20 opened new positions — a net loss of 17 holders — while 80 trimmed existing stakes and 80 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $21.1M. The largest seller was Mesirow Financial Investment Management - Fixed Income, exiting entirely with an estimated $11.9M sold.
- 205 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2022, down from 223 in Q2 2022.
- Funds reported $839M of Amphastar Pharmaceuticals stock for Q3 2022, down 21% quarter-over-quarter.
- 20 funds opened new Amphastar Pharmaceuticals positions in Q3 2022 and 37 closed out, a net change of -17 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2022 was T. Rowe Price Associates, an estimated $21.1M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2022 was Mesirow Financial Investment Management - Fixed Income, an estimated $11.9M sold.
Based on aggregated 13F filings for Q3 2022.